[Comment] Moving Beyond Aspirin After Percutaneous Coronary Intervention: 10-Year Results From the HOST-EXAM Trial

Why It Matters

The findings signal a shift toward P2Y12 inhibitor monotherapy, potentially improving outcomes and reducing gastrointestinal complications, prompting guideline revisions and changes in prescribing habits.

Key Takeaways

• Clopidogrel monotherapy outperformed aspirin over ten years
• Composite cardiovascular events reduced by 15% with clopidogrel
• Major bleeding decreased 20% compared to aspirin group
• Trial included diverse PCI patients across multiple centers
• Guideline committees may reconsider aspirin as default therapy

Pulse Analysis

Aspirin has been the cornerstone of secondary prevention for coronary artery disease for more than half a century. By irreversibly inhibiting cyclooxygenase‑1, it reduces thromboxane‑A2–mediated platelet aggregation, but it also impairs protective prostaglandins, increasing gastrointestinal bleeding risk. Much of the supporting evidence predates modern drug‑eluting stents, high‑intensity statins, and contemporary dual‑antiplatelet strategies. In recent years, P2Y12 inhibitors such as clopidogrel, prasugrel, and ticagrelor have demonstrated more potent and selective platelet inhibition, prompting clinicians to question whether aspirin remains the optimal single‑agent therapy after percutaneous coronary intervention (PCI).

The HOST‑EXAM trial enrolled 5,530 patients who had undergone successful PCI and were free of major events at one year. 2 years. 02). 73). Subgroup analyses showed consistent benefit across age, diabetes status, and stent type, underscoring the robustness of the findings.

These long‑term results are likely to influence upcoming guideline revisions, as professional societies increasingly prioritize net clinical benefit over historical precedent. For clinicians, clopidogrel monotherapy offers a simpler regimen with fewer gastrointestinal side effects, which could improve adherence and reduce healthcare costs associated with bleeding complications. The pharmaceutical market may also see a shift, with manufacturers of P2Y12 inhibitors positioning their products for chronic monotherapy use, while aspirin manufacturers may need to diversify. Ongoing trials evaluating newer agents such as ticagrelor in a monotherapy setting will further clarify the optimal antiplatelet strategy for diverse PCI populations.